Claims for Patent: 10,159,681
✉ Email this page to a colleague
Summary for Patent: 10,159,681
| Title: | Method for on-demand contraception |
| Abstract: | The invention relates to a method for on-demand contraception, which method comprises administering a progestogen agent or progesterone receptor modulator, such as 17a-acetoxy-11b-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal acetate) in a woman, within 72 hours before an intercourse or within 120 hours after the intercourse. |
| Inventor(s): | Andre Ulmann, Erin GAINER, Henri Camille Mathe, Diana Blithe, Lynnette NIEMAN |
| Assignee: | Laboratoire HRA Pharma SAS , US Department of Health and Human Services |
| Application Number: | US15/016,845 |
| Patent Claims: |
1. A method for contraception comprising the step of oral administration a dosage of 20 mg to 30 mg of ulipristal acetate to a woman within 72 hours and up to 120 hours after an unprotected intercourse. 2. The method of claim 1, wherein ulipristal acetate is administered more than 72 hours and up to 120 hours after an unprotected intercourse. 3. The method of claim 1, wherein ulipristal acetate is administered as an oral solid dosage form. 4. The method of claim 3, wherein the oral solid dosage form is a tablet. 5. The method of claim 1, wherein ulipristal acetate is administered as an immediate-release formulation. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch